Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline <i>BRCA</i> or <i>PALB2</i> Mutation
Shun Yu(University of Pennsylvania), Kim A. Reiss(University of Pennsylvania), Peter J. O’Dwyer(University of Pennsylvania), Mark H. O’Hara(University of Pennsylvania), Ronac Mamtani(University of Pennsylvania), Charles Schneider(University of Pennsylvania), Ursina Teitelbaum(University of Pennsylvania), Susan M. Domchek(University of Pennsylvania), Kelsey Spielman(University of Pennsylvania), Katherine L. Nathanson(Translational Therapeutics (United States)), Parul Agarwal(University of Pennsylvania), Heather Symecko(University of Pennsylvania)
Cited by 37
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k